3 hours ago
1
spukkato/iStock via Getty Images
- Arvinas (NASDAQ:ARVN), with its partner Pfizer (PFE), said that the U.S. FDA will review the marketing application for vepdegestrant, to treat patients with advanced or metastatic breast cancer who have previously received endocrine-based therapy.
- The FDA has assigned a target action date of June 5, 2026.
- Vepdegestrant is being jointly developed by Arvinas and Pfizer.
English (US) ·